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This will be a quasi-experimental study design with 
a goal of 60 patients about to undergo surgical or 
invasive procedures requiring an IV catheter 
insertion in the pre op department at West Kendall 
Baptist Hospital (WKBH).
Patient who receive, as standard of practice, 1% 
licocaine prior to IV insertion Will be compared to 
those that did not.
The study sample will consist of 60 patients aged 18 
years and older
To be included in the study participants have to 
have IV accesses established, and the ability to 
express their pain level.
The data collection tool of the study will consist of a 
questionnaire that include patient demographic 
information and questions about pain perception 
and anxiety experienced with IV insertion.
Eligible patients will be introduce to the study with a 
cover letter, and ask to voluntarily participate in the 
study.
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The use of Procalcitonin as a sepsis marker in a community hospital
N. De Oro, AS, MT, (AAB), M. Gauthreaux, MSHSA, BS, MT (ASCP), J. Scott, MD, FACEP, J. Lamoureux, DMD, MSc
This study explores and describes the use of PCT 
in a community hospital setting. We investigated 
its diagnostic accuracy in predicting sepsis and its 
usefulness as an early marker compared to lactic 
acid. It also explored the impact on patient care 
pre and post implementation of procalcitonin in 
regards to direct costs and length of stay for 
sepsis patients. 
Two methods were utilized in this study:
• Method 1: Two comparative groups were 
analyzed in an exploratory descriptive case-
control study with secondary analysis of 
retrospective data over a 19 month period after 
PCT implementation. 
• Method 2: A control group consisting of 
emergency department patients were analyzed 
in a retrospective quasi-experimental study from 
a 19 month period before PCT implementation.  
Procalcitonin (PCT) is a biomarker that aids in the 
diagnosis and monitoring of sepsis. Its levels begin 
to rise as soon as 3-6 hours after an infection is 
detected by the immune system. It has shown to 
be an early and highly specific marker in response 
to sepsis and severe systemic bacterial infections. 
In our community hospital, a majority of admitted
patients are first treated in the emergency
department. As discussed, PCT is a better tool
than the traditional lactic acid and this has resulted
in increased acceptance and utilization in the
emergency room and hospital units. Typically the
length of stay has the greatest influence on cost,
so further review is needed to improve it and
pinpoint savings. Additionally, we need to
investigate if time to treat or treatment plan also
attributes to cost savings.
There was a positive correlation between lactic 
acid and PCT values. In predicting sepsis cases 
with positive blood cultures, PCT (>0.1 ng/mL) had 
a sensitivity of 89.7% while lactic acid’s sensitivity   
(>2mmol/L) was 64.9%. Also, there was a 
significant decrease in cost of hospitalization, 
where the median cost pre-PCT was $10,271 and 
post-PCT was $6,981. Neither, the length of stay 
(hospital or ICU) nor the time to the first antibiotic 
administration demonstrated a difference pre- and 
post- PCT implementation.  
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We confirmed that PCT had a higher sensitivity in 
our hospital than lactic acid, offering a higher 
predictive usefulness in determining patients with 
positive blood cultures. From the results, it was 
suggested to lower the lactic acid cut off to 
1.4mmol/L to improve sensitivity however, it 
decreased specificity and positive predictive value. 
The cost savings observed could be associated 
with a variable outside length of stay, or our 
measurement was not precise enough to show a 
decrease in length of stay.  
Figure 1: Comparison of ROC curves between procalcitonin values and lactic 
acid values to predict sepsis status
Table 1: Descriptive statistics of hospital costs and length of stay by group
Pre-PCT data collection from May 2012 to December 2013, n= 69
Post-PCT data collection from January 2014 to August 2015, n= 165
Pre-PCT
(median, IQR)
Post-PCT
(median, IQR)
Test
Direct Costs ($)
$10,271 
(5,586-16,643)
$6,981 
(4,558-12,576)
Z = 2.034, 
p = 0.042
Hospital LOS 
(days)
5 (4-9) 5 (3-9)
Z = 0.006, 
p = 0.995
ICU LOS (days) 2 (1-3) 2 (1-4)
Z = 0.037, 
p = 0.997
Time to first 
antibiotic 
administration 
(hours: minutes)
2:44 (1:40-4:50) 2:38 (1:31-3:59)
Z = 1.280, 
p = 0.200
